62-OR: Continuous Glucose Monitoring in Pregnancies with Type 1 Diabetes—A Retrospective Study

Introduction 0.01) and lower TIR (p0.05). TIR evolution across the 3rd trimester differed in the presence vs. absence of HDP (p0.05; Figure), with greatest interaction at 28°-316 weeks. Evolution of all metrics differed in the presence vs. absence of RDS (p0.05), with greatest interaction at 28°-336 weeks. Conclusion: The early 3rd trimester, a period of peak insulin resistance, is a critical window to optimize CGM metrics to mitigate APO risk. Disclosure S.A. Fisher: None. M.F. Villa Tamayo: Research Support; Dexcom, Inc. J. Pavan: Other Relationship; Dexcom, Inc. M. Moscoso-Vasquez: Research Support; Dexcom, Inc. Other Relationship; Dexcom, Inc. C. Fabris: Research Support; Novo Nordisk A/S. Other Relationship; Novo Nordisk A/S, Dexcom, Inc. N. Conboy: None. C.M. Niznik: None. L.D. Yee: None. M.A. Kohn: None. E. Kobayashi: None. A.R. Majithia: None. J. Huang: None. T. Tian: None. R. Aaron: None. D.C. Klonoff: Consultant; Afon Technology Ltd, Better Therapeutics, Inc, Glucotrack, LIfecare, Nevro Corp., Novo Nordisk, Samsung, Thirdwayv Inc.